ESMO 2024 | Transdermal estradiol for androgen suppression in locally advanced prostate cancer

Duncan Gilbert • 16 Sep 2024

ESMO 2024

Duncan Gilbert, MA, MRCP, FRCR, PhD, University College London, London, UK, discusses the Phase III PATCH trial (ISRCTN70406718), which investigated transdermal estradiol as an alternative to traditional androgen suppression (LH-RH analogues) in men with locally advanced, treatment-naive prostate cancer. Patients from the STAMPEDE trial (ISRCTN78818544) were additionally recruited and results from the locally advanced cohort were presented. Patients were randomized between standard LH-RH therapy and the experimental use of transdermal estradiol patches. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.